Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.
Tune in for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma. As the complexity of cancer management continues to mount, clinicians frequently face difficult therapeutic decisions that mandate the input from colleagues and various specialties critical for optimizing patient care.
Hear experts provide their perspectives from urology, medical oncology, and radiation oncology on multiple cases:
We will be polling the audience live to interact with the experts on how they would treat.
Register at: https://primetime.bluejeans.com/a2m/register/bcgrjfbp?utm_source=social&utm_medium=post&utm_campaign=registration
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
May 15th 2024The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.